GEn1E finds cures for rare and neglected diseases. We turbocharge development by targeting those therapies with commercial and technical attractiveness: huge unmet need, low competition, clear reimbursement and IP; predictable animal data, objective clinical end point with biomarker, qualify for FDA fast track, tax credit, marketing exclusivity. Lead product is for acute lung injury . 2nd product is non antibiotic for pseudomonas infection in CF